Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of MK-8189 in Alzheimer's Disease
NCT05227118Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in Alzheimer's disease (AD) comparing Elpipodect with Placebo (2 arms). Primary endpoints: Number of Participants Who Experienced an Adverse Event at 42 days and Number of Participants Discontinuing From Study Therapy Due to AE at 42 days. Started Jul 2022; status: completed.
02
Drugs
elpipodect
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05227118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227118.